Skip to content

WholisticResearch Reveals the Best Nootropics of 2023

By API User

In-depth Analysis and Testing Unveil the Leading Brain-Boosting Supplements LONDON, ENGLAND / ACCESSWIRE / August 17, 2023 / WholisticResearch, a leading authority in the realm of cognitive enhancement research, has recently unveiled its list of the top nootropic supplements for 2023. Following rigorous testing and comprehensive analysis, the organization has identified the most effective cognitive … Continued

AI with a heart: Neural network predicts survival of critically ill patients on heart-lung bypass

By API User

A research team led by engineers and cardiologists from Monash University has used artificial intelligence (AI) to develop an algorithm to accurately predict the survival of intensive care patients who need external heart-lung support (ECMO). The ECMO Predictive Algorithm or “ECMO PAL” is the first AI-powered ECMO survival score trained and validated on a large … Continued

Australia’s leading technology fractionator signs US$400m historic joint venture agreement to build 1m litre HaemaFracĀ® facility in Singapore & Cambodia

By API User

AEGROS today announced a ground-breaking agreement to build a fully funded US$400m 1,000,000 litre HaemaFrac® plasma fractionation facility in Singapore, with a sterile fill and finish facility in Cambodia, to supply the Asian market, using local plasma. The joint venture, to be called the Royal Group Plasma Fractionation (RGPF), was formed between The Royal Group … Continued

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

By API User

OMO-103 in Phase 1b clinical trial BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, … Continued

HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

By API User

HanchorBio Received IND Approval of HCB101 Multi-Regional Clinical Trial By Taiwan FDA TAIPEI, TAIWAN and SAN FRANCISCO, CA / ACCESSWIRE / July 24, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate … Continued

BioGX Candida Auris PCR Assay Global Adoption Accelerates

By API User

BIRMINGHAM, AL / ACCESSWIRE / July 24, 2023 / BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities. A complete PCR mix is … Continued

Research to merge human brain cells with AI secures national defence funding

By API User

Monash University-led research into growing human brain cells onto silicon chips, with new continual learning capabilities to transform machine learning, has been awarded almost $600,000 AUD in the prestigious National Intelligence and Security Discovery Research Grants Program. The new research program, led by Associate Professor Adeel Razi, from the Turner Institute for Brain and Mental … Continued

Mould Eradicated! Allied BioServices launches mould remediation service for residential property

By API User

Sydney 19 July 2023 In a ground-breaking first-to-market initiative, Allied BioServices has launched a revolutionary new mould remediation service which will see the business partner with residential property owners and managers to eliminate harmful mould from homes.   The service, which leverages a cutting-edge, long-lasting non-toxic coating technology, responds to the growing incidence of concern … Continued

CLEO Diagnostics Initial Public Offering is now open

By API User

CLEO DIAGNOSTICS (ASX:COV)   Cleo Diagnostics (the Company) is a medical diagnostics entity focused on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer.   SUMMARY OF THE INITIAL PUBLIC OFFERING (IPO)   Eligibility The IPO is open to: Retail, sophisticated and professional investors pursuant to a … Continued